ADVA
1.12.2022 09:02:15 CET | Business Wire | Press release
ADVA (FSE: ADV) today expanded its uCPE solution with Ensemble Cloudlet. This new software is a direct response to the growing demand from enterprises for on-premises cloud solutions. With Ensemble Cloudlet, enterprises can harness edge computing to meet low-latency requirements for applications such as private 5G, AR and smart manufacturing. Removing the need for central hosting also boosts security and makes mission-critical applications more resilient. For CSPs, Ensemble Cloudlet creates an entirely new use case for uCPE. It enables them to offer customers an easily scalable edge cloud with localized control. With Ensemble Cloudlet, CSPs can effortlessly deploy and manage tens of thousands of edge clouds to host customer IT workloads, opening up a wealth of new revenue streams.
“Our Ensemble Cloudlet is a key step in the evolution of the cloud. No longer is it something hosted solely in large, centralized data centers. Now it’s easy to harness the benefits of multi-node clouds right on the customer premises. That means enterprises can utilize applications that require access to compute resources with extremely low latency. It also gives organizations with highly sensitive data the ability to keep all information in a specific area for complete data sovereignty,” said Mike Heffner, GM at Edge Cloud, ADVA. “And for CSPs, our Ensemble Cloudlet opens the door to a world of new opportunities. They already have the infrastructure in place to deliver hybrid workload clouds at the customer edge. Now we’re providing the easy scalability and secure remote management capabilities to make it work. CSPs can start with a single node and then scale up to meet customer demand.”
Ensemble Cloudlet extends traditional uCPE deployments by clustering multiple nodes together in a single cloud and delivering managed on-premises edge computing. With zero-touch provisioning, it makes deployment easy for teams without specialized expertise. Far more cost-efficient than data center cloud solutions, Ensemble Cloudlet also boosts resilience through redundant local cloud controllers and by enabling remote management. This is achieved with ADVA’s Ensemble management and orchestration suite, including Ensemble Orchestrator and Ensemble Virtualization Director, which features automation tools that reduce the need for technical resources and expert personnel.
“The launch of our Ensemble Cloudlet is big news for CSPs. The boom in uCPE deployments puts them in the perfect position to create scalable edge clouds with localized control. Now we’re giving them the tools they require to seize this new opportunity,” commented Brian Van Voorhis, director of PLM at Edge Cloud, ADVA. “For a growing number of applications, the model of a centralized data center cloud just doesn’t fit. Now CSPs can give customers access to the local cloud computing they need for use cases including VR and industrial IoT. From providing standalone resilience when network links fail to reducing backhaul for applications such as video surveillance, our Ensemble Cloudlet will be a game changer.”
Further details on Ensemble Cloudlet are available in this solution brief: https://adva.li/ensemble-cloudlet-solution-brief.
Supporting slides are also available: https://adva.li/ensemble-cloudlet-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005854/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cegid and Silae Join Forces to Create a European Leader in AI-Driven Business Technology9.9.2026 12:32:00 CEST | Press release
Planned Merger Enables Trusted, Fully Integrated Experience Across E-Invoicing, Accounting, Tax, Payroll and HR, Digital Financial Services and Payments for Businesses and their PartnersChristian Pedersen Joins Cegid as CEO to Lead Combined Group Cegid, an AI-driven European leader in cloud business management software for small and medium-sized businesses (SMBs), and accounting professionals, and Silae, France’s leading payroll and human resources platform, today announced their intention to merge. The combination will create a national technology champion and the leading European technology platform for businesses and their partners, helping them grow safely and efficiently with the support of a fully integrated and compliant suite covering their end-to-end financial and administrative needs. Between them, Cegid, following its recent acquisition of Shine, and Silae power the day-to-day accounting, tax, finance and payroll of 2 million end-customers and more than 15,000 chartered acco
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year9.9.2026 12:30:00 CEST | Press release
Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants who were randomized to the 25 mg arm and received an additional doseFor participants randomized to Placebo arm who received first dose of COMP360 25 mg in open-label Part C, data further reinforces that a single 25 mg dose can produce rapid onset, meaningful effect and durabilityFor all participants in Part C who received a 25 mg open-label dose, strong response and remission rates were observed with 40%-45% responders2 and approximately 30% remitters3 across all timepoints 6 weeks post the Part C doseThis 1-year data further supports the belief that, if approved, COMP360 could establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a yearCOMP
New ABB and BCG Report Highlights Growing Role of Direct Current Technologies in Future Power Systems9.9.2026 11:42:00 CEST | Press release
Rapid expansion of AI computing, increasing electrification and rise of renewable energy are driving renewed interest in DC technology as part of future electrical systems Both AC and DC systems have strategically important roles in meeting future electricity demand Establishing common standards and developing DC-specific skills can help accelerate deployment ABB today published a new report, The Strategic Case for Hybrid AC/DC Power: Shaping the Transition to the Next Electrical Architecture, developed in collaboration with Boston Consulting Group (BCG). The report makes the case that direct current (DC) technology is moving from the periphery to the center of industrial, commercial, and digital infrastructure – and that the decisions made by business leaders and policymakers in the next two to three years will determine who shapes that transition and who inherits it. The future of power distribution is not an either-or choice between alternating current (AC) and direct current, but a
Visa and World Bank Group Announce New Risk-Sharing Initiative to Expand Digital Payments and Financial Inclusion in Emerging Markets9.9.2026 11:00:00 CEST | Press release
Visa (NYSE: V), a global leader in digital payments, and the International Finance Corporation (IFC), a member of the World Bank Group focused on the private sector, are partnering on an innovative risk-sharing initiative designed to help expand financial inclusion by increasing access to digital financial services in emerging markets. Under the agreement, IFC will share credit settlement risk for Visa transactions associated with enrolled financial institutions, enabling these institutions to connect more underbanked consumers and small businesses to digital payments. The facility is expected to support approximately $200 million in risk sharing over five years, with an initial focus on 14 countries in Latin America and the Caribbean and reach approximately 50 financial institutions with below-investment grade ratings. Together, Visa and IFC aim to help financial institutions enable millions more people and small businesses to save, spend, borrow, grow, and participate more fully in t
Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities9.9.2026 11:00:00 CEST | Press release
HIGHLIGHTS H1 2026 revenues of €1.89 billion, up +3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area Continued investment in innovation with €426 million invested in R&D (22.5% of sales) Completed strategic investment for treatment of hereditary angioedema (HAE) with acquisition of KalVista Pharmaceuticals EBITDA continues to remain close to 30%, reflecting continued strong profitability and disciplined resource allocation Recent Economic Footprint study highlights Chiesi's contribution to economic development, supporting 56,488 jobs globally, generating €6.0 billion in GDP impact and €2.0 billion in taxes and public revenues worldwide Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 ("H1 2026"). Performance across therapeutic areas and regions Chiesi reported rev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom